The objective of the present study was to evaluate the ability of in-vehicle GPS data loggers to distinguish cognitively normal older drivers with preclinical AD from those without preclinical AD using machine learning methods. Methods We followed naturalistic driving in cognitively normal older drivers...
Pathological changes underlying Alzheimer disease (AD) begin more than 10 years before clinical presentation, and the need for early therapeutic intervention is becoming increasingly recognized. Reisa Sperling and colleagues consider challenges to such a
PJ, Koene T, Blankenstein MA, Scheltens P, van der Flier WM: Preclinical AD predicts decline in memory and executive functions in subjective complaints... Argonde,C,van,... - 《Neurology》 被引量: 102发表: 2013年 Executive functions in multiple sclerosis: an analysis of temporal ordering...
Hypertension increases the risk of Alzheimer's Disease (AD) but blood pressure (BP) in older adults and cognition associated has been conflicting. We reported that arterial stiffness, which may antedate hypertension, better predicts cognitive decline. We investigated the association between BP and ...
INTRODUCTION Depressive symptoms are among early behavioral changes in Alzheimer's disease (AD); however, the relationship between neurodegeneration and depressive symptoms remains inconclusive. To better understand this relationship in preclinical AD, we examined hippocampal volume and depressive symptoms in ...
ADInstruments Blog Support Company Careers Contact Us General Inquiry Request a Quote Technical Support Resources Videos Manuals Brochures Software Downloads Product Documentation Legal Terms of Use Privacy Cookies Safety, Quality & Intended Use Software License Accessibility GDPR Intra-...
Objective To test whether Aβ deposition in preclinical AD, prior to the appearance of cognitive impairment, is associated with changes in quality or quantity of sleep. Design Cross-sectional study conducted from October 2010 to June 2012. Setting General community volunteers at the Washington Univers...
The current study evaluated retinal function using electroretinography (ERG) in cognitively healthy (CH) participants with preclinical Alzheimer’s disease (AD), as classified by cerebral spinal fluid (CSF) Aβ42/Tau ratio. Individuals with normal retina
Gain Therapeutics, Inc. today announced the presentation of new pre-clinical data supporting the potential of its structurally targeted allosteric regulators (STARs) of glucocerebrosidase (GCase) to prevent neurodegeneration in Alzheimer’s disease (AD).